[Alpha Biz= Reporter Kim Minyoung] Yuanta Securities analyzed T&L on the 11th that it is expected to record its best performance in the first half of this year. The investment opinion was 'buy' and the target price was 100,000 won.
"T&L recorded its largest order backlog last month and is expected to achieve its highest-ever performance in the first half of this year," said Yuanta Securities Co. "The balance of overseas orders for wound covering materials in the first quarter reached KRW 20.2 billion, up 32.3% year-on-year and 109.4% from the previous quarter."
Although the order backlog increased last month, the growth of overseas sales in the second quarter is expected to stand out at the bottom of the first quarter as supplies of more than KRW 3 billion were delayed to the second quarter.
Yuanta Securities said, "HERO, which accounts for 62% of T & L's sales, was acquired by a large global consumer goods company C & D in 2022, accelerating the expansion of US offline channels and entry into the European market."
"T&L is also working on new businesses such as microneedle, medical marijuana and chemicals in addition to its main business," Yuanta Securities said. "The stock price is even more undervalued considering its structural growth as a comprehensive material company beyond the trouble patch."
Alphabiz Kim Minyoung (kimmy@alphabiz.co.kr)
